6505--Mycophenolate Mofetil RFP

The Department of Veterans Affairs National Acquisition Center is seeking proposals for Mycophenolate Mofetil capsules and tablets to be distributed through VA and DoD Pharmaceutical Prime Vendor (PPV) Programs. The solicitation requires pricing for four specific line items: 250mg capsules in 100-count and 500-count bottles, and 500mg tablets in 100-count and 500-count bottles. Offerors must provide unique 11-digit NDC numbers and ANDA numbers for each product, and must maintain FDA Good Manufacturing Practice compliance. Proposals were originally due February 24, 2025, but Amendment 0001 extended the deadline to March 4, 2025, at 2:30 PM CT. Contractors must establish business agreements with PPV contractors and have an active Master Agreement and Pharmaceutical Pricing Agreement with the VA Federal Supply Schedule program.

The solicitation is not set aside for any specific category of business and will result in one aggregate award for a base year with four one-year option periods. Annual estimated quantities range from 7,307 to 18,706 bottles depending on package size. Authorized users include VA facilities, DoD facilities, Indian Health Service, Bureau of Prisons, Federal Health Care Center, and Option 2 State Veterans Homes. The contract includes a 60-day implementation period, with the base ordering period starting April 21, 2025. Pricing must incorporate a 0.5% Cost Recovery Fee, and the pharmaceutical preparation will be manufactured under NAICS category 325412 for Pharmaceutical Preparation Manufacturing. The procurement will use Product Service Code 6505 for Drugs and Biologicals, targeting the specific medical needs of various federal healthcare institutions.